Statin therapy is associated with lower prevalence of gut microbiota dysbiosis - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue Nature Année : 2020

Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

1 Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Molecular Bacteriology
2 Nutriomics - Nutrition et obésités: approches systémiques (UMR-S 1269)
3 CBMR - Novo Nordisk Foundation Center for Basic Metabolic Research
4 CHU Pitié-Salpêtrière [AP-HP]
5 Medical Department III – Endocrinology, Nephrology, Rheumatology
6 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
7 EMBL - European Molecular Biology Laboratory [Heidelberg]
8 MDC - Max Delbrück Center for Molecular Medicine [Berlin]
9 DZHK - German Center for Cardiovascular Research
10 VIB-KU Leuven Center for Microbiology [Leuven, Belgium]
11 ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases
12 UMMISCO - Unité de modélisation mathématique et informatique des systèmes complexes [Bondy]
13 GU - Göteborgs Universitet = University of Gothenburg
14 MGP (US 1367) - MetaGenoPolis
15 CHU Tenon [AP-HP]
16 CRSA - Centre de Recherche Saint-Antoine
17 Fudan University [Shanghai]
18 CIC 1418 - CIC - HEGP
19 CIC Paris-Est - Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière]
20 Rigshospitalet [Copenhagen]
21 Department of Metabolism, Digestion and Reproduction
22 NHLI - National Heart and Lung Institute [London]
23 EREN [CRESS - U1153 / UMR_A 1125] - Nutritional Epidemiology Research Team | Equipe de Recherche en Epidémiologie Nutritionnelle
24 Biobyte Solution
25 Department of Biology and Biological Engineering, Chalmers University of Technology
26 EMBL - European Molecular Biology Laboratory
27 University of Heidelberg, Medical Faculty
28 University of Würzburg
29 Wallenberg Laboratory
Nicolas Pons
Emmanuelle Le Chatelier
Nathalie Galleron
  • Fonction : Auteur
  • PersonId : 1205248
Benoit Quinquis
  • Fonction : Auteur
  • PersonId : 1205563
Hugo Roume
  • Fonction : Auteur
  • PersonId : 1205735
Metacardis Consortium
  • Fonction : Auteur
Stanislav Dusko Ehrlich
  • Fonction : Auteur
  • PersonId : 1203280
Lars Køber
Ivica Letunic
  • Fonction : Auteur
Jean-Michel Oppert

Résumé

Microbiome community typing analyses have recently identified the Bacteroides2 (Bact2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans1,2. Bact2 is characterized by a high proportion of Bacteroides, a low proportion of Faecalibacterium and low microbial cell densities1,2, and its prevalence varies from 13% in a general population cohort to as high as 78% in patients with inflammatory bowel disease2. Reported changes in stool consistency3 and inflammation status4 during the progression towards obesity and metabolic comorbidities led us to propose that these developments might similarly correlate with an increased prevalence of the potentially dysbiotic Bact2 enterotype. Here, by exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of the cross-sectional MetaCardis Body Mass Index Spectrum cohort (n = 888), we identify statin therapy as a key covariate of microbiome diversification. By focusing on a subcohort of participants that are not medicated with statins, we find that the prevalence of Bact2 correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. Systemic inflammation levels in Bact2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of Bact2 as a dysbiotic microbiome constellation. We also observe that obesity-associated microbiota dysbiosis is negatively associated with statin treatment, resulting in a lower Bact2 prevalence of 5.88% in statin-medicated obese participants. This finding is validated in both the accompanying MetaCardis cardiovascular disease dataset (n = 282) and the independent Flemish Gut Flora Project population cohort (n = 2,345). The potential benefits of statins in this context will require further evaluation in a prospective clinical trial to ascertain whether the effect is reproducible in a randomized population and before considering their application as microbiota-modulating therapeutics.
Fichier principal
Vignette du fichier
Vieira-Silva.Nature.2020.pdf (732.01 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02964351 , version 1 (22-02-2024)

Identifiants

Citer

Sara Vieira-Silva, Gwen Falony, Eugeni Belda, Trine Nielsen, Judith Aron-Wisnewsky, et al.. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature, 2020, 581 (7808), pp.310-315. ⟨10.1038/s41586-020-2269-x⟩. ⟨hal-02964351⟩
206 Consultations
9 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More